An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer

Abstract Background Immuno-radiotherapy may improve outcomes for patients with advanced solid tumors, although optimized combination modalities remain unclear. Here, we report the colorectal (CRC) cohort analysis from the SABR-PDL1 trial that evaluated the PD-L1 inhibitor atezolizumab in combination...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Antonin Levy, Daphné Morel, Matthieu Texier, Roger Sun, Jerome Durand-Labrunie, Maria E Rodriguez-Ruiz, Severine Racadot, Stéphane Supiot, Nicolas Magné, Stacy Cyrille, Guillaume Louvel, Christophe Massard, Loic Verlingue, Fanny Bouquet, Alberto Bustillos, Lisa Bouarroudj, Clément Quevrin, Céline Clémenson, Michele Mondini, Lydia Meziani, Lambros Tselikas, Rastilav Bahleda, Antoine Hollebecque, Eric Deutsch
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-03-01
coleção:	Molecular Cancer
Acesso em linha:	https://doi.org/10.1186/s12943-024-01970-8
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!